Gut microbiota and metabolome distinctive features in Parkinson disease: Focus on levodopa and levodopa‐carbidopa intrajejunal gel.

MLA

Melis, Marta, et al. “Gut Microbiota and Metabolome Distinctive Features in Parkinson Disease: Focus on Levodopa and Levodopa‐carbidopa Intrajejunal Gel.” European Journal of Neurology, vol. 28, no. 4, Apr. 2021, pp. 1198–209. EBSCOhost, https://doi.org/10.1111/ene.14644.

APA

Melis, M., Vascellari, S., Santoru, M. L., Oppo, V., Fabbri, M., Sarchioto, M., Murgia, D., Zibetti, M., Lopiano, L., Serra, A., Palmas, V., Pisanu, S., Perra, D., Madau, V., Cusano, R., Uva, P., Mereu, A., Contu, P., Morelli, M., & Atzori, L. (2021). Gut microbiota and metabolome distinctive features in Parkinson disease: Focus on levodopa and levodopa‐carbidopa intrajejunal gel. European Journal of Neurology, 28(4), 1198–1209. https://doi.org/10.1111/ene.14644

Chicago

Melis, Marta, Sarah Vascellari, Maria Laura Santoru, Valentina Oppo, Margherita Fabbri, Marianna Sarchioto, Daniela Murgia, et al. 2021. “Gut Microbiota and Metabolome Distinctive Features in Parkinson Disease: Focus on Levodopa and Levodopa‐carbidopa Intrajejunal Gel.” European Journal of Neurology 28 (4): 1198–1209. doi:10.1111/ene.14644.